ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3168-Clayton-Monash-Children-s-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
5
trial(s) found.
NCT06208657
Paed
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (
OPTIMISE
)
Irinotecan
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Temozolomide
alkylating agent
cancer therapy
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT05327894
Paed
Phase 3
Recruiting
Interfant-21
International Collaborative Treatment Protocol for Infants Under One Year with KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Blinatumomab
Prednisone
bispecific T-cell engager,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
glucocorticoid
immuno-oncology therapy,CD19-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT05230758
Paed
Phase 3
Recruiting
Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Medulloblastoma Patients (
Met-Med-Can
)
biguanide antihyperglycaemic agent
placebo
Medulloblastoma
NSW
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (WITHDRAWN)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT04625907
Radonc
Phase 1 / Phase 2
Recruiting
FaR-RMS
: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Cyclophosphamide
Dactinomycin
Doxorubicin
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
Irinotecan
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
Rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT02724163
Paed
Phase 3
Recruiting
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy (
Myechild01
)
anti-CD33 antibody-drug conjugate
Acute myeloid leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Recruitment Country and State
NSW (5)
VIC (5)
WA (5)
QLD (4)
SA (3)
NZ (2)
Phase
Phase 1 / Phase 2 (2)
Phase 3 (3)
Trial Type
Paed (4)
Paed (1)
Radonc (1)
Cancer Therapy Class
PI3K
20%
PI3K delta
20%
PI3Kalpha
20%
mTOR
20%
mTORC1
20%
mTORC2
20%
CD19
20%
FGFR
20%
FGFR1
20%
FGFR1/2/3
20%
FGFR2
20%
FGFR3
20%
FGFR4
20%
KIT
20%
PDGFR
20%
RET
20%
VEGFR
20%
CD33
20%
Facility
2145 - Westmead - The Children's Hospital at Westmead (5)
3052 - Parkville - Royal Children's Hospital Melbourne (5)
3168 - Clayton - Monash Children's Hospital (5)
6009 - Perth - Perth Children's Hospital (5)
2031 - Randwick - Sydney Children's Hospital (4)
2305 - New Lambton Heights - John Hunter Children's Hospital (4)
4101 - South Brisbane - Queensland Children's Hospital (4)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (3)
NZ.1023 - Grafton - Starship Children's Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
Cancer Type
Cancer
Solid tumour
Central nervous system cancer
Neurological cancer
Haematological malignancy
Leukaemia
Sarcoma
Acute lymphoblastic leukaemia
Lymphoid leukaemia
Mixed phenotype acute leukaemia
Central nervous system primitive neuroectodermal tumour
Ewing family of tumours
Medulloblastoma
Rhabdomyosarcoma
Soft tissue sarcoma
Acute myeloid leukaemia
Myeloid leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy